{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:52:08Z","timestamp":1760298728777},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T00:00:00Z","timestamp":1368748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s12272-013-0124-4","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T05:19:32Z","timestamp":1368681572000},"page":"966-972","source":"Crossref","is-referenced-by-count":1,"title":["Improved dosage form of the combined alendronate and calcitriol (Maxmarvil\u00ae) on the absorption of alendronate in Korean postmenopausal women"],"prefix":"10.1007","volume":"36","author":[{"given":"Yoon-Sok","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Jun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,17]]},"reference":[{"key":"124_CR1","unstructured":"Byun, D., and J. Mok. 2013. Endoscopic comparison of enterocoating alendronate with calcitriol combined drug and alendronate in Korean postmenopausal women. The Korean Journal of Internal Medicine (in press)."},{"key":"124_CR2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings, S.R., and L.J. Melton. 2002. Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 1761\u20131767.","journal-title":"Lancet"},{"key":"124_CR3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF01623002","volume":"3","author":"BJ Gertz","year":"1993","unstructured":"Gertz, B.J., S.D. Holland, W.F. Kline, B.K. Matuszewski, and A.G. Porras. 1993. Clinical pharmacology of alendronate sodium. Osteoporosis International 3: S13\u2013S16.","journal-title":"Osteoporosis International"},{"key":"124_CR4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","volume":"58","author":"BJ Gertz","year":"1995","unstructured":"Gertz, B.J., S.D. Holland, W.F. Kline, B.K. Matuszewski, A. Freeman, H. Quan, K.C. Lasseter, J.C. Mucklow, and A.G. Porras. 1995. Studies of the oral bioavailability of alendronate. Clinical Pharmacology and Therapeutics 58: 288\u2013298.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"124_CR5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejps.2012.04.002","volume":"46","author":"H-K Han","year":"2012","unstructured":"Han, H.-K., H.-J. Shin, and D.H. Ha. 2012. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. European Journal of Pharmaceutical Sciences 46: 500\u2013507.","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"124_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00774-004-0590-3","volume":"23","author":"J Iwamoto","year":"2005","unstructured":"Iwamoto, J., T. Takeda, Y. Sato, and M. Uzawa. 2005. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. Journal of Bone and Mineral Metabolism 23: 238\u2013422.","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"124_CR7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00774-004-0508-0","volume":"22","author":"K Kushida","year":"2004","unstructured":"Kushida, K., M. Shiraki, T. Nakamura, H. Kishimoto, H. Morii, K. Yamamoto, K. Kaneda, M. Fukunaga, T. Inoue, M. Nakashima, and H. Orimo. 2004. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: A 3-year follow-up study. Journal of Bone and Mineral Metabolism 22: 462\u2013468.","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"124_CR8","first-page":"137","volume":"36","author":"Y-R Lee","year":"2006","unstructured":"Lee, Y.-R., S.K. Jung, S.K. Yang, K.H. Choi, Y.C. Shin, H.G. Jeon, S. Kang, and H.J. Lee. 2006. Bioequivalence of Daewoong alendronate tablet to Fosamax table (sodium alendronate 70\u00a0mg). Journal of Korean Pharmaceutical Sciences 36: 137\u2013142.","journal-title":"Journal of Korean Pharmaceutical Sciences"},{"key":"124_CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin, J.H. 1996. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18: 75\u201385.","journal-title":"Bone"},{"key":"124_CR10","volume-title":"Sample size tables for clinical studies","author":"D Machin","year":"1997","unstructured":"Machin, D., M. Campbell, P. Fayers, and A. Pinol. 1997. Sample size tables for clinical studies, 2nd ed. Malden, MA: Blackwell Science.","edition":"2"},{"key":"124_CR11","first-page":"1411","volume-title":"Williams textbook of endocrinology","author":"RD Monk","year":"2003","unstructured":"Monk, R.D., and D.A. Bushinsky. 2003. Kidney stones. In Williams textbook of endocrinology, ed. P.R. Larsen, H.M. Kronenberg, S. Melmed, and K.S. Polonsky, 1411\u20131425. Philadelphia: WB Saunders."},{"key":"124_CR12","first-page":"1227","volume":"20","author":"S Naruse","year":"2004","unstructured":"Naruse, S., A. Hisaka, H. Watanabe, T. Taniguchi, Y. Kato, K. Tani, and H. Arizono. 2004. Pharmacokinetic study of alendronate in postmenopausal Japanese women. Rinsho Iyaku 20: 1227\u20131234.","journal-title":"Rinsho Iyaku"},{"key":"124_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0378-4347(01)00551-5","volume":"768","author":"P Ptacek","year":"2002","unstructured":"Ptacek, P., J. Klima, and J. Macek. 2002. Determination of aldendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. Journal of Chromatography B 768: 111\u2013116.","journal-title":"Journal of Chromatography B"},{"key":"124_CR14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras, A.G., S.D. Holland, and B.J. Gertz. 1999. Pharmacokinetics of alendronate. Clinical Pharmacokinetics 36: 315\u2013328.","journal-title":"Clinical Pharmacokinetics"},{"key":"124_CR15","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00198-006-0200-4","volume":"17","author":"Y Rhee","year":"2006","unstructured":"Rhee, Y., M. Kang, Y. Min, D. Byun, Y. Chung, C. Ahn, K. Baek, J. Mok, D. Kim, D. Kim, H. Kim, Y. Kim, S. Myoung, D. Kim, and S.-K. Lim. 2006. Effects of a combined alendronate and calcitriol agent (Maxmarvil\u00ae) on bone metabolism in Korean postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study. Osteoporosis International 17: 1801\u20131807.","journal-title":"Osteoporosis International"},{"key":"124_CR16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato, M., W. Grasser, N. Endo, R. Akins, H. Simmons, D.D. Thompson, E. Golub, and G.A. Rodan. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation 88: 2095\u20132105.","journal-title":"Journal of Clinical Investigation"},{"key":"124_CR17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1507\/endocrj.45.191","volume":"45","author":"M Shiraki","year":"1998","unstructured":"Shiraki, M., K. Kushida, M. Fukunaga, H. Kishimoto, K. Kaneda, H. Minaguchi, T. Inoue, A. Tomita, Y. Nagata, M. Nakashima, and H. Orimo. 1998. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocrine Journal 45: 191\u2013201.","journal-title":"Endocrine Journal"},{"key":"124_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s001980050214","volume":"10","author":"M Shiraki","year":"1999","unstructured":"Shiraki, M., K. Kushida, M. Fukunaga, H. Kishimoto, M. Taga, T. Nakamura, K. Kaneda, H. Minaguchi, T. Inoue, H. Morii, A. Tomita, K. Yamamoto, Y. Nagata, M. Nakashima, and H. Orimo. 1999. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporosis International 10: 183\u2013192.","journal-title":"Osteoporosis International"},{"key":"124_CR19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1023\/A:1008626026484","volume":"20","author":"RW Sparidans","year":"1998","unstructured":"Sparidans, R.W., I.M. Twiss, and S. Talbot. 1998. Bisphosphonates in bone diseases. Pharmacy World & Science 20: 206\u2013213.","journal-title":"Pharmacy World & Science"},{"key":"124_CR20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts, N.B., and D.L. Diab. 2010. Long-term use of bisphosphonates in osteoporosis. Journal of Clinical Endocrinology and Metabolism 95: 1555\u20131565.","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"124_CR21","volume-title":"Biostatistical analysis","author":"JH Zar","year":"1984","unstructured":"Zar, J.H. 1984. Biostatistical analysis, 2nd ed. Englewood Cliffs: Prentice-Hall.","edition":"2"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-013-0124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-013-0124-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-013-0124-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T06:57:30Z","timestamp":1559458650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-013-0124-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,17]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s12272-013-0124-4","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,17]]}}}